BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $59.75 -0.99%
Revenue Growth %: +13.2%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
CRMT, PKE, HELE, More
Revenue Growth %: +13.2%
Financial Fact:
Net product revenues: 278.26M
Today's EPS Names:
CRMT, PKE, HELE, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q3 EPS of $0.04, $0.14 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $113.4 million versus the consensus estimate of $113.2 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Lowered to $62 at RBC Capital
- General Mills (GIS) Tops Q4 EPS by 14c, Beats on Revenue; Offers FY27 EPS Guidance
- Culp, Inc. (CULP) Misses Q4 EPS by 12c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
